Litcius/Paper detail

Light-triggered dual-modality drug release of self-assembled prodrug-nanoparticles for synergistic photodynamic and hypoxia-activated therapy

Dongyang Zhao, Wenhui Tao, Songhao Li, Lingxiao Li, Yixin Sun, Guanting Li, Gang Wang, Yang Wang, Bin Lin, Cong Luo, Yongjun Wang, Maosheng Cheng, Zhonggui He, Jin Sun

2020Nanoscale Horizons60 citationsDOI

Abstract

Photodynamic therapy (PDT) leads to tumor hypoxia which could be utilized for the activation of hypoxia-activated prodrugs (HAPs). However, conventional photosensitizer-loaded nanoformulations suffer from an aggregation-caused quenching (ACQ) effect, which limits the efficiency of PDT and synergistic therapy. Herein, prodrug-nanoparticles (NPs) are prepared by the self-assembly of heterodimeric prodrugs composed of pyropheophorbide a (PPa), hypoxia-activated prodrug PR104A, and a thioether or thioketal linkage. In addition, a novel dual-modality drug release pattern is proposed on the basis of the structural states of prodrug-NPs. Under light irradiation, PR104A is released via photoinduced electron transfer (PET) due to the aggregation state of prodrugs. With the disassembly of prodrug-NPs, the ACQ effect is relieved, and PPa produces singlet oxygen which further promotes the reactive oxygen species (ROS)-sensitive release of PR104A. Such prodrug-NPs turn the disadvantage of the ACQ effect to facilitate drug release, demonstrating high-efficiency synergy in combination with PDT and hypoxia-activated therapy.

Topics & Concepts

ProdrugPhotodynamic therapyHypoxia (environmental)NanoparticleChemistryDrug deliveryTumor hypoxiaDrugPharmacologyCombinatorial chemistryNanotechnologyMaterials scienceMedicineOxygenRadiation therapyBiochemistryInternal medicineOrganic chemistryNanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesLuminescence and Fluorescent Materials